SCHEMBL26656293

SCHEMBL26656293

CC(C)(C)OC(=O)NCc1cc(F)c(F)cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.43
CA1 P00915 3/20 0.43
CA2 P00918 3/20 0.43
CA9 Q16790 3/20 0.43
CA12 O43570 2/20 0.43
KDM4A O75164 1/20 0.41
CACNA1H O95180 1/20 0.40
CACNA1B Q00975 1/20 0.40
CACNA1C Q13936 1/20 0.40
GRM2 Q14416 1/20 0.40
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
NAMPT P43490 1/20 0.39
PDPK1 O15530 1/20 0.39
STK17B O94768 1/20 0.38
STK17A Q9UEE5 1/20 0.38
SCN9A Q15858 1/20 0.38
DYRK1A Q13627 1/20 0.38
CA4 P22748 1/20 0.38
CA7 P43166 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30670723 0.89 STK17B (0.47) L3MBTL1CA1CA2CA9CA12
SCHEMBL26657670 0.89 STK17B (0.47) L3MBTL1CA1CA2CA9CA12
SCHEMBL13952493 0.81 CA1 (0.43) L3MBTL1CA1CA2CA9CA12
SCHEMBL19794866 0.81 TRPA1 (0.49) CA1CA2CA9CA12CACNA1H
SCHEMBL16282482 0.80 GRM2 (0.45) L3MBTL1CA1CA2CA9CA12
SCHEMBL31380341 0.79 CACNA1H (0.47) L3MBTL1CA1CA2CA9CA12
SCHEMBL3633138 0.78 KDM4A (0.54) L3MBTL1CA1CA2CA9CA12
SCHEMBL13881841 0.78 AAK1 (0.43) L3MBTL1CA1CA2CA9CA12
SCHEMBL31625175 0.78 L3MBTL1 (0.43) L3MBTL1CA1CA2CA9CA12
SCHEMBL17680512 0.77 L3MBTL1 (0.43) L3MBTL1CA1CA2CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250281483-A1 TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF Astellas Engineered Small Molecules US, Incorporated 2025-09-11 US disclosed
EP-4511112-A1 TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF Astellas Engineered Small Molecules US, Incorporated (US) 2025-02-26 EP disclosed
WO-2023205415-A1 TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF MITOBRIDGE INC. (US) 2023-10-26 WO disclosed
WO-2023205415-A1 TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF MITOBRIDGE INC. (US) 2023-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250281483-A1 TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF TFEB, MITF, CREBBP L3MBTL1 1495/4885CA1 4883/4885CA2 4668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.